Zinc, Copper, and Magnesium and Risks for All-cause, Cancer, and Cardiovascular Mortality
Overview
Affiliations
Background: Experimental data suggest that zinc, copper, and magnesium are involved in carcinogenesis and atherogenesis. Few longitudinal studies have related these minerals to cancer or cardiovascular disease mortality in a population.
Methods: Data from the Paris Prospective Study 2, a cohort of 4035 men age 30-60 years at baseline, were used to assess the association between serum zinc, copper, and magnesium and all-cause, cancer, and cardiovascular disease mortality. Serum mineral values measured at baseline were divided into quartiles and classified into low (1st quartile, referent group), medium (2nd-3rd quartiles), and high (4th quartile) values. During 18-year follow up, 339 deaths occurred, 176 as a result of cancer and 56 of cardiovascular origin. Relative risks (RRs) for each element were inferred using Cox's proportional hazard model after controlling for various potential confounders.
Results: High copper values (4th quartile) were associated with a 50% increase in RRs for all-cause deaths (RR = 1.5; 95% confidence interval = 1.1-2.1), a 40% increase for cancer mortality (1.4; 0.9-2.2), and a 30% increase for cardiovascular mortality (1.3; 0.6-2.8) compared with low values (1st quartile). High magnesium values were negatively related to mortality with a 40% decrease in RR for all-cause (0.6; 0.4-0.8) and cardiovascular deaths (0.6; 0.2-1.2) and by 50% for cancer deaths (0.5; 0.3-0.8). Additionally, subjects with a combination of low zinc and high copper values had synergistically increased all-cause (2.6; 1.4-5.0) and cancer (2.7; 1.0-7.3) mortality risks. Similarly, combined low zinc and high magnesium values were associated with decreased all-cause (0.2; 0.1-0.5) and cancer (0.2; 0.1-0.8) mortality risks.
Conclusions: High serum copper, low serum magnesium, and concomitance of low serum zinc with high serum copper or low serum magnesium contribute to an increased mortality risk in middle-aged men.
Jamebozorgi K, Kooshki A, Saljoughi M, Sanjari M, Ahmadi Z, Mosavi Mirzaei S PLoS One. 2025; 20(2):e0317731.
PMID: 39899648 PMC: 11790114. DOI: 10.1371/journal.pone.0317731.
Gogineni R, Arumugam S, Muninathan N, Baskaran K Cureus. 2024; 16(10):e71696.
PMID: 39553080 PMC: 11568654. DOI: 10.7759/cureus.71696.
Martinez-Morata I, Schilling K, Glabonjat R, Domingo-Relloso A, Mayer M, McGraw K Circulation. 2024; 150(10):758-769.
PMID: 39087344 PMC: 11371385. DOI: 10.1161/CIRCULATIONAHA.124.069414.
Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death.
Gao X, Zhao H, Liu J, Wang M, Dai Z, Hao W Adv Sci (Weinh). 2024; 11(30):e2401396.
PMID: 38859590 PMC: 11321675. DOI: 10.1002/advs.202401396.
Kasahara C, Tamura T, Wakai K, Tamada Y, Kato Y, Kubo Y Public Health Nutr. 2024; 27(1):e135.
PMID: 38698584 PMC: 11148834. DOI: 10.1017/S1368980024000831.